Physician profile
H Lantz
NPI 1093780546
$1,096.50
in general payments reported to CMS, 2019-2025
15 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $19.46 · 2021: $85.89 · 2022: $233 · 2023: $164 · 2024: $171 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $279.83 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $249.15 | 2021-2024 | Dupixent, Libtayo |
| Smith+Nephew, INC. | $118.50 | 2022-2024 | Stravix |
| Incyte Corporation | $85.76 | 2021-2024 | Opzelura |
| Sun Pharmaceutical Industries INC. | $80.96 | 2023-2025 | Ilumya |
| Janssen Biotech, INC. | $55.62 | 2022-2023 | Tremfya |
| Organogenesis INC. | $50.61 | 2024 | |
| Ucb, INC. | $48.11 | 2025 | Bimzelx |
| Leo Pharma INC. | $23.67 | 2025 | Adbry |
| Amgen INC. | $19.18 | 2023 | Otezla |
| Lilly USA, LLC | $19.15 | 2022 | |
| Integra Lifesciences Corporation | $18.70 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Cipher Pharmaceuticals US LLC | $16.88 | 2025 | Spinosad, Natroba |
| Genentech USA, INC. | $16.61 | 2021 | |
| Access Pro Medical, LLC | $13.77 | 2025 | Matriderm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw H Lantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.